ArticleFrontiers in bioengineering and biotechnology2026
Integrating biosafety and osteogenic efficacy: a translational pathway of fluorinated porcine-derived hydroxyapatite for bone regeneration.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Element doping has emerged as a promising strategy to enhance the osteogenic capacity of bone substitutes. Among various dopants, fluoride has attracted considerable attention because of its modulatory effects on bone regeneration; however, a critical gap remains regarding the long-term systemic safety of fluoride-doped materials before clinical translation. A fluoride-specific, biosafety-oriented translational pathway was therefore applied to complement conventional biomaterial assessment. Methods: Fluorinated porcine-derived hydroxyapatite (FPHA) was prepared through a chemical and thermal process and characterized to confirm the stable incorporation of fluoride into the hydroxyapatite lattice. A dual-validation dissolution assay was developed to estimate the total fluoride content of FPHA. Multiple in vitro models simulating physiological and artificial extreme environments were established to evaluate material degradation, associated fluoride release, and changes in the surrounding medium pH. A 26-week beagle dog study was conducted to evaluate serum fluoride concentrations, blood biochemical parameters, ridge contour maintenance, and bone formation. Results: Characterization confirmed stable fluoride incorporation into FPHA, which exhibited a lower degradation rate than deproteinized bovine bone mineral (DBBM) and controlled fluoride release under simulated physiological conditions. In the 26-week beagle dog study, serum fluoride concentrations remained comparable to baseline levels, with no clinically relevant adverse changes in blood biochemical parameters. FPHA also showed effective long-term ridge contour maintenance and enhanced bone formation compared to DBBM. Discussion: Collectively, these findings provide preclinical evidence supporting the preliminary long-term biosafety profile and osteogenic performance of FPHA, illustrating a fluoride-specific, biosafety-oriented evaluation strategy for ion-functionalized biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.